News Agency
The Times

Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD to Evaluate DR30303 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Gastric or Gastroesophageal Junction Cancer

  • Written by PR Newswire
Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD to Evaluate DR30303 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Gastric or Gastroesophageal Junction Cancer

HANGZHOU, China, Dec. 16, 2022 /PRNewswire/ -- Hangzhou, Zhejiang, China, [December 9th, 2022], Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announced that it has entered into a clinical trial collaboration agreement...

Read more: Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD to Evaluate DR30303 in...

Commercial Leasing Mistakes That Can Cost Your Business

Signing a commercial lease is a significant commitment, and the mistakes made at the outset of a tenancy can follow a business for the entire duration of the agreement. Many tenants enter lease negotiations without a full understanding of what... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion